CA1235065A - Stabilized 4-carbamoyl-imidazolium-5-olate preparations - Google Patents

Stabilized 4-carbamoyl-imidazolium-5-olate preparations

Info

Publication number
CA1235065A
CA1235065A CA000475351A CA475351A CA1235065A CA 1235065 A CA1235065 A CA 1235065A CA 000475351 A CA000475351 A CA 000475351A CA 475351 A CA475351 A CA 475351A CA 1235065 A CA1235065 A CA 1235065A
Authority
CA
Canada
Prior art keywords
acid
imidazolium
carbamoyl
olate
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
CA000475351A
Other languages
English (en)
French (fr)
Inventor
Keiichi Kato
Hisao Tobiki
Muneo Hara
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sumitomo Pharma Co Ltd
Original Assignee
Sumitomo Pharmaceuticals Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sumitomo Pharmaceuticals Co Ltd filed Critical Sumitomo Pharmaceuticals Co Ltd
Application granted granted Critical
Publication of CA1235065A publication Critical patent/CA1235065A/en
Expired legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/4174Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2013Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA000475351A 1984-03-05 1985-02-27 Stabilized 4-carbamoyl-imidazolium-5-olate preparations Expired CA1235065A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP59043265A JPS60185727A (ja) 1984-03-05 1984-03-05 4−カルバモイルイミダゾリウム−5−オレ−ト製剤の安定化法
JP43265/84 1984-03-05

Publications (1)

Publication Number Publication Date
CA1235065A true CA1235065A (en) 1988-04-12

Family

ID=12659008

Family Applications (1)

Application Number Title Priority Date Filing Date
CA000475351A Expired CA1235065A (en) 1984-03-05 1985-02-27 Stabilized 4-carbamoyl-imidazolium-5-olate preparations

Country Status (5)

Country Link
EP (1) EP0159777A1 (enExample)
JP (1) JPS60185727A (enExample)
KR (1) KR850006131A (enExample)
CA (1) CA1235065A (enExample)
ES (1) ES8700936A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2196460A4 (en) * 2007-09-14 2011-11-23 Fujifilm Corp Sulphonic acid salt compound of a 4-carbamoyl-5-hydroxyimidazole derivative

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR950010150B1 (ko) * 1986-01-14 1995-09-11 쥬우가이세이야꾸 가부시끼가이샤 니코란딜 함유 주사제의 안정화 방법
JP5458777B2 (ja) 2009-09-28 2014-04-02 株式会社ジェイテクト ダブルカルダンジョイントのカップリングヨーク
JP2013082706A (ja) * 2011-09-28 2013-05-09 Fujifilm Corp 5−ヒドロキシ−1h−イミダゾール−4−カルボキサミド水和物の結晶
TWI594988B (zh) * 2011-09-28 2017-08-11 富士軟片股份有限公司 5-羥基-1h-咪唑-4-甲醯胺.3/4水合物及其結晶之製造方法
RU2630682C2 (ru) 2011-09-28 2017-09-12 Фуджифилм Корпорэйшн Кристалл 5-гидрокси-1н-имидазол-4-карбоксамид•3/4 гидрата, способ его получения и кристалл 5-гидрокси-1н-имидазол-4-карбоксамида гидрата
BR112014026250A2 (pt) * 2013-01-15 2017-06-27 Fujifilm Corp preparação de produto sólido embalado contendo 5-hidroxi-1h-imidazola-4-carboxamida ou sal do mesmo, ou hidrato dos mesmos
RU2603137C1 (ru) * 2013-01-15 2016-11-20 Фуджифилм Корпорэйшн Сульфат 5-гидрокси-1н-имидазол-4-карбоксамида
SI2946780T1 (sl) 2013-01-15 2017-05-31 Fujifilm Corporation Tableta, ki vsebuje 5-hidroksi-1h-imidazol-4-karboksamid
EP3686189B1 (en) * 2017-10-27 2021-09-01 FUJIFILM Corporation Production method for 5-hydroxy-1h-imidazole-4-carboxamide-3/4hydrate

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4181731A (en) * 1976-09-07 1980-01-01 Sumitomo Chemical Company, Limited Novel therapeutic application of 4-carbamoyl-5-hydroxyimidazole
DE3176849D1 (en) * 1980-11-05 1988-09-29 Sumitomo Chemical Co Pharmaceutical composition comprising 4-carbamoyl-imidazolium-5-olate

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2196460A4 (en) * 2007-09-14 2011-11-23 Fujifilm Corp Sulphonic acid salt compound of a 4-carbamoyl-5-hydroxyimidazole derivative
US8664405B2 (en) 2007-09-14 2014-03-04 Fujifilm Corporation Sulfonic acid salt compound of 4-carbamoyl-5-hydroxy-imidazole derivative

Also Published As

Publication number Publication date
KR850006131A (ko) 1985-10-02
ES540907A0 (es) 1986-11-16
JPS60185727A (ja) 1985-09-21
EP0159777A1 (en) 1985-10-30
JPH0137376B2 (enExample) 1989-08-07
ES8700936A1 (es) 1986-11-16

Similar Documents

Publication Publication Date Title
AU725622B2 (en) Pharmaceutical composition stabilized with a basic agent
CA1338889C (en) Morphine containing composition
US3873694A (en) Direct compression tabletting composition and pharmaceutical tablets produced therefrom
CA1235065A (en) Stabilized 4-carbamoyl-imidazolium-5-olate preparations
IE870120L (en) Histamine h2-antagonist compositions.
JPH11514629A (ja) 安定な甲状腺ホルモン含有薬剤
EP0159852A2 (en) Directly compressible pharmaceutical compositions
US4666919A (en) Stabilized pharmaceutical composition containing an isocarbostyril derivative
AU743043B2 (en) Pharmaceutical preparations of cilansetron stabilized against racemization
EP0952823B1 (en) Stabilized pharmaceutical compositions and process for the preparation thereof
HU208626B (en) Process for producing stabile compositions containing calcium-pantothenate
JP2974550B2 (ja) 経口投与用固体組成物
KR920008161B1 (ko) 오메프라졸 경구용 약제의 제조방법
JPH0242811B2 (enExample)
WO2022075436A1 (en) A method of producing thyroid hormone-containing formulation
KR20020070309A (ko) 비등성 히스타민 h2 길항제 조성물
JPH05201858A (ja) 固形製剤
EP0293975A1 (en) Dry, rapidly soluble, compositions of beta-lactam antibiotics
KR960004018B1 (ko) L-글루타민과 수용성아줄렌 복합 항궤양용 제제의 안정화 방법
JP2003095939A (ja) 安定なプラバスタチンナトリウム錠
JPH09268127A (ja) ビタミンb1誘導体含有固形製剤組成物
MXPA00012906A (en) Pharmaceutical levothyroxine preparation
MXPA98006166A (en) Pharmaceutical preparations of cilansetron stabilized against the racemizac
MXPA99003792A (en) Pharmaceutical forms for the oral administration of me
MXPA01003797A (en) HIGH PURITY COMPOSITION COMPRISING (7&agr;,17&agr;)- 17-HYDROXY- 7-METHYL- 19-NOR-17-PREGN- 5(10)-EN-20-YN-3-ONE

Legal Events

Date Code Title Description
MKEX Expiry